Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envonalkib
- Development stage
- Phase 3
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Envonalkib is a novel, potent small molecule inhibitor of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC), where it has demonstrated significant efficacy, including improved progression-free survival and central nervous system activity compared to first-generation ALK inhibitors such as crizotinib. Envonalkib acts by selectively inhibiting the ALK tyrosine kinase, thereby blocking downstream signaling pathways that drive tumor growth in cancers harboring ALK rearrangements. The drug was developed by Chia Tai Tianqing Pharmaceutical Group and is marketed under the brand name Anluoqing in China for late-stage or metastatic NSCLC[2][4][5][6][7].
- Brand names
- Anluoqing
- Other names
- Envonalkib citrate
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on envonalkib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envonalkib.